查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1463113

格林巴利症候群市场,占有率,规模,趋势,行业分析报告:依治疗药物,给药途径,分销管道,地区和细分市场预测2024-2032 年

Guillain-Barre Syndrome Market Share, Size, Trends, Industry Analysis Report, By Therapeutics (Intravenous Immunoglobulin, Plasma Exchange, Others); By Route of Administration; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032
出版日期: | 出版商: Polaris Market Research | 英文 119 Pages | 商品交期: 最快1-2个工作天内

价格

根据Polaris Market Research最新研究显示，到2032年，全球格林巴利综合症市场规模预计将达到9.6058亿美元。该研究报告提供了对当前市场动态的详细洞察，并对未来市场成长进行了分析。

美国食品药物管理局 (USFDA) 的药品审批加速计画在促进製药业新产品审批大幅增加方面发挥着至关重要的作用。该倡议旨在加速创新药物的开发和使用，特别是那些解决未满足的医疗需求的药物。透过简化监管流程，美国食品药物管理局为製药公司将新疗法推向市场创造了更有效的途径，最终使患有各种疾病的患者受益。

新产品核准量迅速增加的一个值得注意的领域是格林-巴利综合症 (GBS) 市场。GBS 是一种罕见的神经系统疾病，其特征是免疫系统攻击週边神经，可导致肌肉无力和严重併发症。对加速药物审批的重视刺激了 GBS 领域的研究和开发，从而推出了创新疗法来应对这种疾病的独特课题。

製药公司正在增加对 GBS 研究的投资，利用监管机构简化的流程来加快临床试验并更快地将潜在的治疗方法推向市场。这不仅扩大了 GBS 患者的治疗前景，也创造了更具竞争力的市场环境，鼓励治疗的进一步创新和进步。

FDA 批准的 GBS 药物数量的增加证明了药物批准加速计划的积极影响，为医疗保健专业人员提供了管理和治疗这种具有课题性的疾病的新工具。如果製药业继续采用这种加速审批系统，它可能会改变罕见疾病治疗的格局，为患有格林-巴利综合症等疾病的患者带来希望并改善治疗结果。

格林巴利综合症市场报告亮点

由于免疫球蛋白输注易于使用，预计未来几年将出现最高成长。

由于静脉免疫球蛋白治疗的功效，母药市场占据最大市场占有率

由于自体免疫病例的增加，预计医院药房部门将占据更大的收入占有率。

由于人口老化和该领域的技术创新，亚太地区将快速成长。

目录

第一章简介

第二章执行摘要

第三章研究方法论

第 4 章：格林巴利症候群全球市场洞察

  • 格林巴利症候群市场 - 分销通路快照
  • 格林巴利症候群市场动态
    • 驱动因素和机遇
      • 格林-巴利症候群盛行率增加
      • 吉兰-巴利症候群的风险增加
    • 限制因素和课题
      • 缺乏治疗意识可能会阻碍市场成长
  • PESTEL 分析
  • 格林巴利症候群市场分销通路趋势
  • 价值链分析
  • COVID-19 影响分析

第五章格林巴利症候群的全球市场（依治疗领域）

  • 主要发现
  • 介绍
  • 静脉注射免疫球蛋白
  • 血浆置换术
  • 其他

第六章 吉兰-巴利症候群的全球市场（依给药途径）

  • 主要发现
  • 介绍
  • 口服
  • 家长

第七章格林巴利症候群全球市场，依分销管道

  • 主要发现
  • 介绍
  • 医院药房
  • 零售药店
  • 其他

第八章全球格林巴利症候群市场（依地区）

  • 主要发现
  • 介绍
    • 格林巴利症候群市场评估，依地区，2019-2032
  • 格林巴利症候群市场 - 北美
    • 北美：格林巴利症候群市场，依治疗领域，2019-2032
    • 北美：格林巴利症候群市场，依通路划分，2019-2032
    • 北美：格林巴利症候群市场，依给药途径，2019-2032 年
    • 格林巴利症候群市场—美国
    • 格林巴利症候群市场－加拿大
  • 格林巴利症候群市场—欧洲
    • 欧洲：格林巴利症候群市场，依治疗领域，2019-2032
    • 欧洲：格林巴利症候群市场，依分销管道划分，2019-2032
    • 欧洲：格林巴利症候群市场，依给药途径划分，2019-2032 年
    • 格林巴利症候群市场—英国
    • 格林巴利症候群市场—法国
    • 格林巴利症候群市场 - 德国
    • 格林巴利症候群市场 - 义大利
    • 格林巴利症候群市场－西班牙
    • 格林巴利症候群市场－荷兰
    • 格林巴利症候群市场 - 俄罗斯
  • 格林巴利症候群市场 - 亚太地区
    • 亚太地区：格林巴利症候群市场，依治疗领域，2019-2032
    • 亚太地区：格林巴利症候群市场，依通路划分，2019-2032 年
    • 亚太地区：格林巴利症候群市场，依给药途径划分，2019-2032 年
    • 格林巴利症候群市场—中国
    • 格林巴利症候群市场—印度
    • 格林巴利症候群市场 – 马来西亚
    • 格林巴利症候群市场 - 日本
    • 格林巴利症候群市场-印度尼西亚
    • 格林巴利症候群市场 - 韩国
  • 格林巴利症候群市场 - 中东和非洲
    • 中东和非洲：格林巴利症候群市场，依治疗领域，2019-2032
    • 中东和非洲：格林巴利症候群市场，依通路划分，2019-2032
    • 中东和非洲：格林巴利症候群市场，依给药途径划分，2019-2032 年
    • 格林巴利症候群市场－沙乌地阿拉伯
    • 格林巴利症候群市场 - 阿联酋
    • 格林巴利症候群市场—以色列
    • 格林巴利症候群市场—南非
  • 格林巴利症候群市场 - 拉丁美洲
    • 拉丁美洲：格林巴利症候群市场，依治疗领域，2019-2032
    • 拉丁美洲：格林巴利综合症市场，依分销管道划分，2019-2032 年
    • 拉丁美洲：格林巴利症候群市场，依给药途径划分，2019-2032 年
    • 格林巴利症候群市场 - 墨西哥
    • 格林巴利症候群市场－巴西
    • 格林巴利症候群市场—阿根廷

第9章 竞争格局

  • 扩张和收购分析
    • 扩张
    • 获得
  • 合作/协作/合约/展览

第十章公司简介

  • Annexon Inc.
  • Bayer AG
  • Biotest AG
  • Cellenkos Inc
  • China Biologic Products Holdings Inc
  • CSL Limited
  • Grifols S A
  • Kedrion Biopharma Inc
  • Octapharma AG
  • Takeda Pharmaceutical Company Limited
Product Code: PM4787

The global guillain-barre syndrome market size is expected to reach USD 960.58 million by 2032, according to a new study by Polaris Market Research. The report "Guillain-Barre Syndrome Market Share, Size, Trends, Industry Analysis Report, By Therapeutics (Intravenous Immunoglobulin, Plasma Exchange, Others); By Route of Administration; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The accelerated drug approval initiative by the United States Food and Drug Administration (USFDA) has played a pivotal role in fostering a significant rise in new product approvals within the pharmaceutical industry. This initiative aims to expedite the development and availability of innovative drugs, particularly those addressing unmet medical needs. By streamlining regulatory processes, the USFDA has created a more efficient pathway for pharmaceutical companies to bring novel treatments to market, ultimately benefiting patients with various medical conditions.

One notable area experiencing a surge in new product approvals is the market for Guillain-Barre Syndrome (GBS). GBS is a rare neurological disorder characterized by the immune system attacking the peripheral nerves, leading to muscle weakness and potentially severe complications. The heightened focus on accelerating drug approvals has spurred research and development efforts in the GBS space, resulting in the introduction of innovative therapies designed to address the unique challenges posed by this disorder.

Pharmaceutical companies are increasingly investing in GBS research, leveraging the streamlined regulatory processes to expedite clinical trials and bring potential treatments to market faster. This has not only broadened the therapeutic landscape for GBS patients but has also created a more competitive market environment, encouraging further innovation and advancements in treatment options.

The positive impact of the accelerated drug approval initiative is evident in the growing number of FDA-approved drugs for GBS, providing healthcare professionals with additional tools to manage and treat this challenging condition. As the pharmaceutical industry continues to embrace these expedited pathways, it holds the potential to transform the landscape of rare disease treatment, offering hope and improved outcomes for patients with conditions like Guillain-Barre Syndrome.

Guillain-Barre Syndrome Market Report Highlights

Intravenous immunoglobulin segment is anticipated to witness the highest growth in the coming years due to its ease of application.

Parental segment accounted for the largest market share owing to its effectiveness in intravenous immunoglobulin therapy.

Hospital Pharmacies segment is projected to experience a larger revenue share due to the growing number of auto-immune cases.

Asia Pacific will grow rapidly, attributable to the presence of a geriatric population, and innovations in the sector

The global players include Annexon, Bayer, Biotest, Cellenkos, China Biologic Products Holdings, CSL Limited, & Grifols.

Polaris Market Research has segmented the Guillain-Barre syndrome market report based on therapeutics, route of administration, distribution channel and region:

Guillain-Barre Syndrome, Therapeutics Outlook (Revenue - USD Million, 2019 - 2032)

  • Intravenous Immunoglobulin
  • Plasma Exchange
  • Others

Guillain-Barre Syndrome, Route of Administration Outlook (Revenue - USD Million, 2019 - 2032)

  • Oral
  • Parental

Guillain-Barre Syndrome, Distribution Channel Outlook (Revenue - USD Million, 2019 - 2032)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Guillain-Barre Syndrome, Regional Outlook (Revenue - USD Million, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Australia
  • Rest of APAC
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of MEA

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Guillain-Barre Syndrome Market Insights

  • 4.1. Guillain-Barre Syndrome Market - Distribution Channel Snapshot
  • 4.2. Guillain-Barre Syndrome Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising prevalence of Guillain-Barre syndrome cases
      • 4.2.1.2. Increase in the risk of having Guillain-Barre syndrome
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Lower awareness about the treatment is likely to impede market growth
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Guillain-Barre Syndrome Market Distribution Channel Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Guillain-Barre Syndrome Market, by Therapeutic Area

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • 5.3. Intravenous Immunoglobulin
    • 5.3.1. Global Guillain-Barre Syndrome Market, by Intravenous Immunoglobulin, by Region, 2019-2032 (USD Million)
  • 5.4. Plasma Exchange
    • 5.4.1. Global Guillain-Barre Syndrome Market, by Plasma Exchange, by Region, 2019-2032 (USD Million)
  • 5.5. Others
    • 5.5.1. Global Guillain-Barre Syndrome Market, by Others, by Region, 2019-2032 (USD Million)

6. Global Guillain-Barre Syndrome Market, by Route of Administration

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • 6.3. Oral
    • 6.3.1. Global Guillain-Barre Syndrome Market, by Oral, by Region, 2019-2032 (USD Million)
  • 6.4. Parental
    • 6.4.1. Global Guillain-Barre Syndrome Market, by Parental, by Region, 2019-2032 (USD Million)

7. Global Guillain-Barre Syndrome Market, by Distribution Channel

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • 7.3. Hospital Pharmacies
    • 7.3.1. Global Guillain-Barre Syndrome Market, by Hospital Pharmacies, By Region, 2019-2032 (USD Million)
  • 7.4. Retail Pharmacies
    • 7.4.1. Global Guillain-Barre Syndrome Market, by Retail Pharmacies, By Region, 2019-2032 (USD Million)
  • 7.5. Others
    • 7.5.1. Global Guillain-Barre Syndrome Market, by Others, By Region, 2019-2032 (USD Million)

8. Global Guillain-Barre Syndrome Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Guillain-Barre Syndrome Market Assessment, By Geography, 2019-2032 (USD Million)
  • 8.3. Guillain-Barre Syndrome Market - North America
    • 8.3.1. North America: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
    • 8.3.2. North America: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.3.3. North America: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
    • 8.3.4. Guillain-Barre Syndrome Market - U.S.
      • 8.3.4.1. U.S.: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
      • 8.3.4.2. U.S.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.3.4.3. U.S.: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
    • 8.3.5. Guillain-Barre Syndrome Market - Canada
      • 8.3.5.1. Canada: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
      • 8.3.5.2. Canada.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.3.5.3. Canada: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • 8.4. Guillain-Barre Syndrome Market - Europe
    • 8.4.1. Europe: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
    • 8.4.2. Europe.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.4.3. Europe: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
    • 8.4.4. Guillain-Barre Syndrome Market - UK
      • 8.4.4.1. UK: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
      • 8.4.4.2. UK.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.4.4.3. UK: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
    • 8.4.5. Guillain-Barre Syndrome Market - France
      • 8.4.5.1. France: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
      • 8.4.5.2. France.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.4.5.3. France: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
    • 8.4.6. Guillain-Barre Syndrome Market - Germany
      • 8.4.6.1. Germany: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
      • 8.4.6.2. Germany.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.4.6.3. Germany: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
    • 8.4.7. Guillain-Barre Syndrome Market - Italy
      • 8.4.7.1. Italy: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
      • 8.4.7.2. Italy.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.4.7.3. Italy: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
    • 8.4.8. Guillain-Barre Syndrome Market - Spain
      • 8.4.8.1. Spain: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
      • 8.4.8.2. Spain.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.4.8.3. Spain: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
    • 8.4.9. Guillain-Barre Syndrome Market - Netherlands
      • 8.4.9.1. Netherlands: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
      • 8.4.9.2. Netherlands.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.4.9.3. Netherlands: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
    • 8.4.10. Guillain-Barre Syndrome Market - Russia
      • 8.4.10.1. Russia: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
      • 8.4.10.2. Russia.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.4.10.3. Russia: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • 8.5. Guillain-Barre Syndrome Market - Asia Pacific
    • 8.5.1. Asia Pacific: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
    • 8.5.2. Asia Pacific.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.5.3. Asia Pacific: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
    • 8.5.4. Guillain-Barre Syndrome Market - China
      • 8.5.4.1. China: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
      • 8.5.4.2. China.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.5.4.3. China: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
    • 8.5.5. Guillain-Barre Syndrome Market - India
      • 8.5.5.1. India: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
      • 8.5.5.2. India.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.5.5.3. India: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
    • 8.5.6. Guillain-Barre Syndrome Market - Malaysia
      • 8.5.6.1. Malaysia: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
      • 8.5.6.2. Malaysia.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.5.6.3. Malaysia: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
    • 8.5.7. Guillain-Barre Syndrome Market - Japan
      • 8.5.7.1. Japan: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
      • 8.5.7.2. Japan.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.5.7.3. Japan: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
    • 8.5.8. Guillain-Barre Syndrome Market - Indonesia
      • 8.5.8.1. Indonesia: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
      • 8.5.8.2. Indonesia.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.5.8.3. Indonesia: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
    • 8.5.9. Guillain-Barre Syndrome Market - South Korea
      • 8.5.9.1. South Korea: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
      • 8.5.9.2. South Korea.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.5.9.3. South Korea: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • 8.6. Guillain-Barre Syndrome Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
    • 8.6.2. Middle East & Africa.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.6.3. Middle East & Africa: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
    • 8.6.4. Guillain-Barre Syndrome Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
      • 8.6.4.2. Saudi Arabia.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.6.4.3. Saudi Arabia: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
    • 8.6.5. Guillain-Barre Syndrome Market - UAE
      • 8.6.5.1. UAE: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
      • 8.6.5.2. UAE.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.6.5.3. UAE: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
    • 8.6.6. Guillain-Barre Syndrome Market - Israel
      • 8.6.6.1. Israel: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
      • 8.6.6.2. Israel.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.6.6.3. Israel: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
    • 8.6.7. Guillain-Barre Syndrome Market - South Africa
      • 8.6.7.1. South Africa: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
      • 8.6.7.2. South Africa.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.6.7.3. South Africa: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • 8.7. Guillain-Barre Syndrome Market - Latin America
    • 8.7.1. Latin America: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
    • 8.7.2. Latin America.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.7.3. Latin America: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
    • 8.7.4. Guillain-Barre Syndrome Market - Mexico
      • 8.7.4.1. Mexico: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
      • 8.7.4.2. Mexico.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.7.4.3. Mexico: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
    • 8.7.5. Guillain-Barre Syndrome Market - Brazil
      • 8.7.5.1. Brazil: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
      • 8.7.5.2. Brazil.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.7.5.3. Brazil: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
    • 8.7.6. Guillain-Barre Syndrome Market - Argentina
      • 8.7.6.1. Argentina: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
      • 8.7.6.2. Argentina.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.7.6.3. Argentina: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Annexon Inc.
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Bayer AG
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Biotest AG
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Cellenkos Inc
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. China Biologic Products Holdings Inc
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. CSL Limited
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Grifols S A
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Kedrion Biopharma Inc
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Octapharma AG
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Takeda Pharmaceutical Company Limited
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development

List of Tables

  • Table 1 Global Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 2 Global Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 3 Global Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 4 Guillain-Barre Syndrome Market Assessment, By Geography, 2019-2032 (USD Million)
  • Table 5 North America: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 6 North America: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 7 North America: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 8 U.S.: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 9 U.S.: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 10 U.S.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 11 Canada: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 12 Canada: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 13 Canada: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 14 Europe: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 15 Europe: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 16 Europe: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 17 UK: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 18 UK: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 19 UK: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 20 France: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 21 France: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 22 France: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 23 Germany: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 24 Germany: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 25 Germany: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 26 Italy: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 27 Italy: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 28 Italy: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 29 Spain: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 30 Spain: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 31 Spain: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 32 Netherlands: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 33 Netherlands: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 34 Netherlands: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 35 Russia: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 36 Russia: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 37 Russia: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 38 Asia Pacific: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 39 Asia Pacific: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 40 Asia Pacific: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 41 China: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 42 China: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 43 China: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 44 India: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 45 India: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 46 India: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 47 Malaysia: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 48 Malaysia: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 49 Malaysia: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 50 Japan: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 51 Japan: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 52 Japan: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 53 Indonesia: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 54 Indonesia: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 55 Indonesia: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 56 South Korea: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 57 South Korea: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 58 South Korea: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 59 Middle East & Africa: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 60 Middle East & Africa: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 61 Middle East & Africa: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 62 Saudi Arabia: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 63 Saudi Arabia: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 64 Saudi Arabia: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 65 UAE: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 66 UAE: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 67 UAE: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 68 Israel: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 69 Israel: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 70 Israel: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 71 South Africa: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 72 South Africa: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 73 South Africa: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 74 Latin America: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 75 Latin America: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 76 Latin America: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 77 Mexico: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 78 Mexico: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 79 Mexico: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 80 Brazil: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 81 Brazil: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 82 Brazil: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 83 Argentina: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 84 Argentina: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 85 Argentina: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)

List of Figures

  • Figure 1. Global Guillain-Barre Syndrome Market, 2019-2032 (USD Million)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Route of Administration
  • Figure 7. Global Guillain-Barre Syndrome Market, by Route of Administration, 2022 & 2032 (USD Million)
  • Figure 8. Market by Therapeutic Area
  • Figure 9. Global Guillain-Barre Syndrome Market, by Therapeutic Area, 2022 & 2032 (USD Million)
  • Figure 10. Market by Distribution Channel
  • Figure 11. Global Guillain-Barre Syndrome Market, by Distribution Channel, 2022 & 2032 (USD Million)
  • Figure 12. Guillain-Barre Syndrome Market Assessment, By Geography, 2019-2032 (USD Million)
  • Figure 13. Strategic Analysis - Guillain-Barre Syndrome Market